Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Extracellular vesicle mimics made from iPS cell-derived mesenchymal stem cells improve the treatment of metastatic prostate cancer

Fig. 1

Selective uptake of iPSC-MSC nanovesicles by prostate cancer cells vs. non-tumor cells. a 1 × 105 PC3 PCa cells, human vascular smooth muscle cells (SMCs), and human umbilical vein endothelial cells (HUVECs) in 1 ml medium were incubated with 1 × 1010 DiI-labeled extracellular vesicles, nanoghosts, nanovesicles, or liposomes (FormuMax) for 15 min, 1 h, or 3 h, then washed and analyzed by flow cytometry for DiI signal. b, c LORs of uptake by PC3 cells vs. SMCs or HUVECs were calculated with the formula Log2 [(% of DiI+ PC3/% of DiI+ SMC/HUVEC)/(% of DiI PC3/% of DiI SMC/HUVEC)]. d, e The selective uptake of nanovesicles stored for up to 6 weeks by PC3 cells vs. SMCs was analyzed as in a and b. N = 3 in all assays, *p < 0.05 vs. liposomes, ^p < 0.05 vs. nanoghosts, #p < 0.05 vs. extracellular vesicles

Back to article page